Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Patent
1997-11-21
2000-11-28
Geist, Gary
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
514349, 514352, 514357, 514417, 514470, 514535, 514539, 546309, 548471, 548475, 549303, 549304, 560 39, 560 41, 560 42, 560 43, 564152, 564155, 564158, 564168, A01N 3718, A01N 3712, A01N 3744, A61K 31165
Patent
active
061536520
ABSTRACT:
Disclosed are compounds which inhibit .beta.-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed pharmaceutical compositions comprising a compound which inhibits .beta.-amyloid peptide release and/or its synthesis as well as methods for treating Alheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.
REFERENCES:
patent: 3657341 (1972-04-01), Thorne
patent: 5478857 (1995-12-01), Clemens
Pazhanisamy et al., Biochemistry, 1989, 28, p6875-6882
Database CAPLUS on STN, Acc. No. 1995:810448, Dovey et al., `Aspartyl proteinase inhibitor preparation, assay and use for treatment of Alzheimer's Disease,` CA 2129689 (abstract), 1995.
Database CAPLUS on STN, Acc. No. 1995:837456, Cordell et al., `Preparation of peptide analogs as inhibitors of .beta.-amyoid protein production.` WO 9509838 (abstract), 1995.
Chemical Abstracts, vol. 54, No. 11, Jun. 10, 1960.
Ogawa, et al., Chem. Pharm. Bull., 36(6):1957-1962 (1988).
Hlavacek, et al., Collection of Czechoslovak Chemical Communications, 41:1257-1264 (1976).
Doherty, et al., J. Biol. Chem., 189:447-454 (1951).
Pazhanisamy, et al., Biochemistry, 28:6875-6882 (1989) See in particular, Compound 3 at p. 6876.
Smith, et al., .beta.-APP Processing as a Therapeutic Target for Alzheimer's Disease, Current Pharmaceutical Design, 3 439-445 (1997).
Cordell, .beta.-Amyloid Formation as a Potential Therapeutic Target for Alzheimer's Disease, Annu. Rev. Pharmacol. Toxicol. 34:69-89 (1994).
Audia James E.
Eid Clark N.
Latimer Lee H.
Mabry Thomas E.
Nissen Jeffrey S.
Davis Brian J.
Elan Pharmaceuticals Inc.
Eli Lilly & Company
Geist Gary
LandOfFree
N-(aryl/heteroaryl/alkylacetyl) amino acid amides, pharmaceutica does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with N-(aryl/heteroaryl/alkylacetyl) amino acid amides, pharmaceutica, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and N-(aryl/heteroaryl/alkylacetyl) amino acid amides, pharmaceutica will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1726288